| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 203 | 2024 | 1421 | 20.650 |
Why?
|
| Phenylbutyrates | 7 | 2023 | 69 | 2.770 |
Why?
|
| Neuroprotective Agents | 24 | 2020 | 941 | 2.760 |
Why?
|
| Clinical Trials as Topic | 36 | 2023 | 7901 | 2.080 |
Why?
|
| Superoxide Dismutase | 21 | 2018 | 596 | 2.040 |
Why?
|
| Benzothiazoles | 5 | 2016 | 247 | 1.560 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 34 | 1.510 |
Why?
|
| Motor Neurons | 20 | 2024 | 851 | 1.410 |
Why?
|
| Ceftriaxone | 5 | 2016 | 168 | 1.290 |
Why?
|
| Ubiquinone | 9 | 2019 | 188 | 1.260 |
Why?
|
| Motor Neuron Disease | 9 | 2021 | 106 | 1.250 |
Why?
|
| Muscle Strength Dynamometer | 2 | 2017 | 43 | 1.170 |
Why?
|
| Riluzole | 10 | 2014 | 55 | 1.150 |
Why?
|
| Muscle Strength | 9 | 2020 | 586 | 1.150 |
Why?
|
| Double-Blind Method | 40 | 2023 | 12017 | 1.100 |
Why?
|
| Huntington Disease | 17 | 2020 | 1111 | 1.090 |
Why?
|
| Hydroxylamines | 3 | 2018 | 40 | 0.840 |
Why?
|
| Disease Progression | 42 | 2023 | 13256 | 0.830 |
Why?
|
| Vital Capacity | 9 | 2022 | 922 | 0.810 |
Why?
|
| Clinical Trials, Phase II as Topic | 6 | 2014 | 627 | 0.800 |
Why?
|
| Spinal Cord | 10 | 2021 | 1807 | 0.770 |
Why?
|
| Phenylenediamines | 1 | 2021 | 90 | 0.750 |
Why?
|
| Carbamates | 1 | 2021 | 195 | 0.690 |
Why?
|
| Neurology | 4 | 2022 | 762 | 0.680 |
Why?
|
| Nervous System Diseases | 5 | 2020 | 1617 | 0.630 |
Why?
|
| Fructose | 5 | 2010 | 288 | 0.620 |
Why?
|
| Oligodeoxyribonucleotides, Antisense | 2 | 2018 | 57 | 0.610 |
Why?
|
| Humans | 242 | 2024 | 742088 | 0.570 |
Why?
|
| Neurosciences | 1 | 2020 | 347 | 0.530 |
Why?
|
| Research Design | 14 | 2023 | 5979 | 0.500 |
Why?
|
| Middle Aged | 119 | 2023 | 213127 | 0.490 |
Why?
|
| Evoked Potentials, Motor | 2 | 2020 | 456 | 0.470 |
Why?
|
| Hand Strength | 4 | 2012 | 444 | 0.450 |
Why?
|
| Muscle, Skeletal | 12 | 2019 | 4933 | 0.440 |
Why?
|
| Cerebral Cortex | 3 | 2021 | 5705 | 0.440 |
Why?
|
| Oligonucleotides, Antisense | 3 | 2022 | 433 | 0.430 |
Why?
|
| Severity of Illness Index | 15 | 2020 | 15530 | 0.430 |
Why?
|
| Treatment Outcome | 41 | 2021 | 62966 | 0.430 |
Why?
|
| Quadriplegia | 1 | 2014 | 225 | 0.430 |
Why?
|
| Male | 133 | 2023 | 349538 | 0.430 |
Why?
|
| Patient Selection | 6 | 2016 | 4214 | 0.420 |
Why?
|
| Isometric Contraction | 4 | 2017 | 147 | 0.420 |
Why?
|
| Antioxidants | 4 | 2016 | 1659 | 0.420 |
Why?
|
| Nerve Growth Factors | 4 | 2022 | 576 | 0.420 |
Why?
|
| Neurodegenerative Diseases | 5 | 2024 | 1060 | 0.400 |
Why?
|
| Female | 129 | 2023 | 379592 | 0.400 |
Why?
|
| Neural Inhibition | 1 | 2015 | 598 | 0.400 |
Why?
|
| Patient Compliance | 3 | 2017 | 2680 | 0.400 |
Why?
|
| Minocycline | 4 | 2017 | 163 | 0.390 |
Why?
|
| Mesenchymal Stem Cells | 1 | 2022 | 1625 | 0.390 |
Why?
|
| Respiratory Insufficiency | 4 | 2021 | 1199 | 0.390 |
Why?
|
| Aged | 82 | 2023 | 162944 | 0.390 |
Why?
|
| Uric Acid | 5 | 2023 | 760 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2022 | 10943 | 0.360 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2019 | 495 | 0.350 |
Why?
|
| Information Services | 1 | 2010 | 244 | 0.340 |
Why?
|
| Mexiletine | 2 | 2020 | 31 | 0.340 |
Why?
|
| Adult | 89 | 2023 | 213712 | 0.330 |
Why?
|
| Frontotemporal Dementia | 2 | 2021 | 246 | 0.310 |
Why?
|
| tau Proteins | 3 | 2021 | 1860 | 0.310 |
Why?
|
| Lithium Chloride | 1 | 2008 | 87 | 0.310 |
Why?
|
| Drug Delivery Systems | 3 | 2013 | 2217 | 0.310 |
Why?
|
| Pyridines | 6 | 2021 | 2818 | 0.310 |
Why?
|
| Protein C | 2 | 2019 | 138 | 0.300 |
Why?
|
| Pentoxifylline | 2 | 2009 | 55 | 0.300 |
Why?
|
| Creatine | 4 | 2019 | 421 | 0.300 |
Why?
|
| Muscles | 2 | 2011 | 1617 | 0.300 |
Why?
|
| Age of Onset | 11 | 2019 | 3266 | 0.290 |
Why?
|
| Neuroglia | 3 | 2017 | 925 | 0.290 |
Why?
|
| Phosphodiesterase Inhibitors | 2 | 2018 | 215 | 0.280 |
Why?
|
| Injections, Spinal | 5 | 2022 | 303 | 0.280 |
Why?
|
| Pyrazines | 3 | 2019 | 1231 | 0.280 |
Why?
|
| Imidazoles | 3 | 2019 | 1205 | 0.270 |
Why?
|
| Randomized Controlled Trials as Topic | 11 | 2022 | 9941 | 0.270 |
Why?
|
| Nerve Degeneration | 4 | 2007 | 748 | 0.270 |
Why?
|
| Telephone | 1 | 2009 | 617 | 0.270 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2018 | 3770 | 0.270 |
Why?
|
| Brain | 13 | 2021 | 26343 | 0.260 |
Why?
|
| Biological Specimen Banks | 1 | 2010 | 707 | 0.260 |
Why?
|
| Endpoint Determination | 4 | 2022 | 600 | 0.260 |
Why?
|
| Survival Analysis | 11 | 2023 | 10248 | 0.260 |
Why?
|
| Disability Evaluation | 3 | 2010 | 1827 | 0.260 |
Why?
|
| Public Opinion | 1 | 2009 | 477 | 0.260 |
Why?
|
| Maximal Voluntary Ventilation | 1 | 2004 | 13 | 0.260 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2018 | 2276 | 0.260 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 2 | 2018 | 236 | 0.250 |
Why?
|
| Neurofilament Proteins | 3 | 2022 | 318 | 0.240 |
Why?
|
| Placebos | 4 | 2013 | 1677 | 0.240 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2004 | 190 | 0.240 |
Why?
|
| Myotonia Congenita | 1 | 2023 | 14 | 0.240 |
Why?
|
| Pyramidal Tracts | 2 | 2013 | 257 | 0.230 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2009 | 789 | 0.230 |
Why?
|
| Lyme Disease | 1 | 2009 | 618 | 0.230 |
Why?
|
| Malignant Hyperthermia | 1 | 2023 | 73 | 0.230 |
Why?
|
| Sulfonamides | 3 | 2010 | 1932 | 0.230 |
Why?
|
| Proteins | 2 | 2015 | 6096 | 0.230 |
Why?
|
| Motor Cortex | 3 | 2021 | 984 | 0.230 |
Why?
|
| Vasodilator Agents | 2 | 2009 | 976 | 0.220 |
Why?
|
| Pyrazoles | 3 | 2010 | 1970 | 0.220 |
Why?
|
| Recovery of Function | 4 | 2022 | 2924 | 0.210 |
Why?
|
| DNA Repeat Expansion | 3 | 2021 | 66 | 0.210 |
Why?
|
| Physical Endurance | 2 | 2017 | 370 | 0.210 |
Why?
|
| Erythropoietin | 1 | 2007 | 724 | 0.210 |
Why?
|
| Gene Targeting | 1 | 2006 | 880 | 0.210 |
Why?
|
| Administration, Oral | 4 | 2021 | 3913 | 0.210 |
Why?
|
| Health Care Surveys | 1 | 2010 | 2451 | 0.210 |
Why?
|
| Fragile X Syndrome | 1 | 2023 | 115 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 1788 | 0.210 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2005 | 449 | 0.200 |
Why?
|
| Single-Blind Method | 5 | 2023 | 1589 | 0.200 |
Why?
|
| Glutathione Peroxidase | 1 | 2002 | 255 | 0.200 |
Why?
|
| Disease Models, Animal | 11 | 2022 | 18006 | 0.190 |
Why?
|
| Intention to Treat Analysis | 2 | 2020 | 425 | 0.190 |
Why?
|
| Magnetics | 1 | 2004 | 609 | 0.190 |
Why?
|
| Animals | 38 | 2023 | 168561 | 0.190 |
Why?
|
| Biomedical Research | 5 | 2020 | 3306 | 0.190 |
Why?
|
| Motor Skills | 3 | 2017 | 518 | 0.190 |
Why?
|
| Multicenter Studies as Topic | 3 | 2013 | 1661 | 0.190 |
Why?
|
| Deoxyguanosine | 1 | 2000 | 84 | 0.190 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 261 | 0.180 |
Why?
|
| Internet | 2 | 2010 | 3062 | 0.180 |
Why?
|
| Central Nervous System | 3 | 2008 | 1354 | 0.180 |
Why?
|
| Communication | 1 | 2014 | 3728 | 0.180 |
Why?
|
| Diabetic Neuropathies | 1 | 2023 | 410 | 0.180 |
Why?
|
| Meningoencephalitis | 2 | 2020 | 78 | 0.180 |
Why?
|
| Enteral Nutrition | 3 | 2020 | 763 | 0.170 |
Why?
|
| Recombinant Proteins | 3 | 2019 | 6608 | 0.170 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 2123 | 0.170 |
Why?
|
| Cromolyn Sodium | 1 | 2019 | 87 | 0.170 |
Why?
|
| Reproducibility of Results | 10 | 2020 | 19862 | 0.170 |
Why?
|
| Patient Dropouts | 2 | 2017 | 421 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 6 | 2022 | 9274 | 0.170 |
Why?
|
| Mitochondria | 4 | 2022 | 3520 | 0.170 |
Why?
|
| Anticonvulsants | 3 | 2021 | 1914 | 0.170 |
Why?
|
| Cross-Over Studies | 2 | 2022 | 2030 | 0.170 |
Why?
|
| Time | 1 | 2020 | 530 | 0.170 |
Why?
|
| Inosine | 2 | 2023 | 133 | 0.170 |
Why?
|
| Enzyme Inhibitors | 2 | 2009 | 3800 | 0.170 |
Why?
|
| Pilot Projects | 7 | 2018 | 8297 | 0.160 |
Why?
|
| Lymphokines | 1 | 2001 | 949 | 0.160 |
Why?
|
| Respiratory Function Tests | 2 | 2020 | 1613 | 0.160 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2019 | 221 | 0.160 |
Why?
|
| Cleft Palate | 1 | 2023 | 558 | 0.150 |
Why?
|
| Drug Combinations | 2 | 2020 | 1961 | 0.150 |
Why?
|
| Quinidine | 1 | 2017 | 57 | 0.150 |
Why?
|
| Dextromethorphan | 1 | 2017 | 38 | 0.150 |
Why?
|
| Survival Rate | 11 | 2019 | 12773 | 0.150 |
Why?
|
| Evidence-Based Medicine | 2 | 2015 | 3611 | 0.150 |
Why?
|
| Academies and Institutes | 1 | 2019 | 317 | 0.150 |
Why?
|
| Cytoprotection | 2 | 2009 | 210 | 0.150 |
Why?
|
| Neuralgia | 1 | 2023 | 568 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2010 | 3760 | 0.150 |
Why?
|
| Oligonucleotides | 1 | 2020 | 572 | 0.150 |
Why?
|
| Longitudinal Studies | 10 | 2019 | 13921 | 0.150 |
Why?
|
| Follow-Up Studies | 17 | 2020 | 39004 | 0.150 |
Why?
|
| Review Literature as Topic | 2 | 2009 | 333 | 0.140 |
Why?
|
| Acetamides | 2 | 2017 | 249 | 0.140 |
Why?
|
| Sulfisoxazole | 1 | 1996 | 8 | 0.140 |
Why?
|
| Spinal Muscular Atrophies of Childhood | 1 | 2017 | 108 | 0.140 |
Why?
|
| Drug Therapy, Combination | 7 | 2019 | 6483 | 0.140 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2002 | 838 | 0.140 |
Why?
|
| Aged, 80 and over | 19 | 2023 | 57683 | 0.140 |
Why?
|
| Health Status | 1 | 2010 | 4030 | 0.140 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 1996 | 28 | 0.140 |
Why?
|
| Neurons | 4 | 2021 | 9325 | 0.140 |
Why?
|
| Chromosomes, Human | 1 | 2018 | 457 | 0.140 |
Why?
|
| RNA-Directed DNA Polymerase | 2 | 2008 | 248 | 0.140 |
Why?
|
| MicroRNAs | 3 | 2020 | 3731 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 2 | 2014 | 2006 | 0.130 |
Why?
|
| Nerve Regeneration | 1 | 2001 | 791 | 0.130 |
Why?
|
| Medical Futility | 2 | 2023 | 126 | 0.130 |
Why?
|
| Research | 2 | 2017 | 1999 | 0.130 |
Why?
|
| Cohort Studies | 17 | 2021 | 40450 | 0.130 |
Why?
|
| Vitamins | 4 | 2019 | 1608 | 0.130 |
Why?
|
| Intermediate Filaments | 2 | 2020 | 175 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 5 | 2014 | 7153 | 0.130 |
Why?
|
| Remission, Spontaneous | 1 | 2015 | 380 | 0.130 |
Why?
|
| Neuropsychological Tests | 3 | 2017 | 6974 | 0.130 |
Why?
|
| Indoles | 1 | 2023 | 1834 | 0.130 |
Why?
|
| Speech | 1 | 2020 | 540 | 0.130 |
Why?
|
| Tamoxifen | 1 | 2019 | 980 | 0.130 |
Why?
|
| Mice, Transgenic | 12 | 2014 | 9735 | 0.130 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 253 | 0.120 |
Why?
|
| Proteomics | 6 | 2012 | 3618 | 0.120 |
Why?
|
| Young Adult | 12 | 2023 | 56350 | 0.120 |
Why?
|
| C-Reactive Protein | 3 | 2022 | 3766 | 0.120 |
Why?
|
| Databases, Factual | 7 | 2019 | 7716 | 0.120 |
Why?
|
| Point Mutation | 2 | 2003 | 1624 | 0.120 |
Why?
|
| Home Care Services | 1 | 2020 | 602 | 0.120 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 1341 | 0.120 |
Why?
|
| Thrombectomy | 1 | 2019 | 679 | 0.120 |
Why?
|
| Proportional Hazards Models | 9 | 2023 | 12344 | 0.120 |
Why?
|
| Formaldehyde | 1 | 2015 | 353 | 0.120 |
Why?
|
| Electrodiagnosis | 3 | 2020 | 154 | 0.120 |
Why?
|
| Time Factors | 12 | 2023 | 40054 | 0.120 |
Why?
|
| Brain Ischemia | 2 | 2019 | 3258 | 0.110 |
Why?
|
| Transcranial Magnetic Stimulation | 2 | 2020 | 1431 | 0.110 |
Why?
|
| Myelin Proteins | 1 | 2014 | 215 | 0.110 |
Why?
|
| Mutation | 9 | 2020 | 29717 | 0.110 |
Why?
|
| Hospice Care | 1 | 2020 | 671 | 0.110 |
Why?
|
| PubMed | 1 | 2013 | 122 | 0.110 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2014 | 839 | 0.110 |
Why?
|
| Mice | 21 | 2022 | 81045 | 0.110 |
Why?
|
| United States | 13 | 2023 | 69693 | 0.110 |
Why?
|
| Propranolol | 1 | 2014 | 502 | 0.110 |
Why?
|
| Gait | 4 | 2000 | 784 | 0.110 |
Why?
|
| Parkinson Disease | 5 | 2014 | 2774 | 0.110 |
Why?
|
| Post-Dural Puncture Headache | 1 | 2013 | 48 | 0.110 |
Why?
|
| Axons | 1 | 2020 | 1681 | 0.110 |
Why?
|
| Toxicity Tests, Chronic | 1 | 2012 | 7 | 0.110 |
Why?
|
| Depression | 2 | 2018 | 7733 | 0.110 |
Why?
|
| Induced Pluripotent Stem Cells | 2 | 2022 | 1728 | 0.110 |
Why?
|
| Telemedicine | 2 | 2020 | 2853 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2004 | 3740 | 0.110 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2014 | 157 | 0.110 |
Why?
|
| High-Throughput Screening Assays | 1 | 2018 | 944 | 0.110 |
Why?
|
| Reference Values | 4 | 2012 | 4982 | 0.110 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2019 | 1262 | 0.100 |
Why?
|
| Predictive Value of Tests | 10 | 2014 | 15056 | 0.100 |
Why?
|
| Career Choice | 1 | 2018 | 743 | 0.100 |
Why?
|
| G-Quadruplexes | 1 | 2014 | 162 | 0.100 |
Why?
|
| Thiazoles | 1 | 1999 | 1484 | 0.100 |
Why?
|
| Exercise Therapy | 2 | 2017 | 904 | 0.100 |
Why?
|
| Vasculitis | 1 | 1995 | 521 | 0.100 |
Why?
|
| Area Under Curve | 2 | 2014 | 1653 | 0.100 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 350 | 0.100 |
Why?
|
| Neuromuscular Junction | 2 | 2019 | 397 | 0.100 |
Why?
|
| Counseling | 1 | 2019 | 1521 | 0.100 |
Why?
|
| Activities of Daily Living | 3 | 2014 | 2414 | 0.100 |
Why?
|
| Vanadium | 1 | 2010 | 53 | 0.100 |
Why?
|
| Apoptosis | 5 | 2012 | 9715 | 0.090 |
Why?
|
| Body Weight | 5 | 2020 | 4664 | 0.090 |
Why?
|
| Suicide, Attempted | 1 | 2019 | 1218 | 0.090 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 438 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2016 | 1459 | 0.090 |
Why?
|
| Retrospective Studies | 15 | 2023 | 77098 | 0.090 |
Why?
|
| DNA Damage | 1 | 2000 | 2423 | 0.090 |
Why?
|
| Oxidative Stress | 1 | 2021 | 3081 | 0.090 |
Why?
|
| Information Management | 1 | 2010 | 98 | 0.090 |
Why?
|
| Patient Participation | 1 | 2019 | 1445 | 0.090 |
Why?
|
| Needles | 1 | 2013 | 448 | 0.090 |
Why?
|
| Aging | 3 | 2007 | 8626 | 0.090 |
Why?
|
| Prognosis | 7 | 2020 | 29010 | 0.090 |
Why?
|
| Cocaine | 1 | 1995 | 1008 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2018 | 1182 | 0.090 |
Why?
|
| Treatment Failure | 3 | 2007 | 2615 | 0.090 |
Why?
|
| Aluminum | 1 | 2010 | 152 | 0.090 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 4 | 2010 | 3862 | 0.090 |
Why?
|
| Suicidal Ideation | 1 | 2019 | 1246 | 0.090 |
Why?
|
| Interleukin-6 | 1 | 2019 | 3199 | 0.090 |
Why?
|
| Quality of Life | 7 | 2023 | 12730 | 0.090 |
Why?
|
| Cell Count | 5 | 2007 | 1831 | 0.090 |
Why?
|
| Phenylacetates | 1 | 2009 | 114 | 0.090 |
Why?
|
| Respiratory Paralysis | 1 | 2009 | 31 | 0.090 |
Why?
|
| Cytokines | 2 | 2021 | 7317 | 0.080 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 847 | 0.080 |
Why?
|
| Dinoprost | 2 | 1999 | 138 | 0.080 |
Why?
|
| Neuropeptide Y | 1 | 1990 | 200 | 0.080 |
Why?
|
| Creatinine | 1 | 2014 | 1916 | 0.080 |
Why?
|
| Galectin 3 | 1 | 2010 | 227 | 0.080 |
Why?
|
| Intermediate Filament Proteins | 1 | 1989 | 269 | 0.080 |
Why?
|
| Coenzymes | 2 | 2005 | 91 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6534 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2014 | 1239 | 0.080 |
Why?
|
| Computer Security | 1 | 2010 | 263 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 1372 | 0.080 |
Why?
|
| Immunomodulation | 1 | 2012 | 540 | 0.080 |
Why?
|
| Adolescent | 8 | 2023 | 85649 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2018 | 2271 | 0.080 |
Why?
|
| Anti-Infective Agents | 1 | 1996 | 971 | 0.080 |
Why?
|
| Gammaretrovirus | 1 | 2008 | 54 | 0.080 |
Why?
|
| Aryldialkylphosphatase | 1 | 2008 | 63 | 0.080 |
Why?
|
| Oxepins | 1 | 2007 | 2 | 0.080 |
Why?
|
| Brain Chemistry | 1 | 2012 | 981 | 0.080 |
Why?
|
| Anthropometry | 1 | 2012 | 1350 | 0.080 |
Why?
|
| Manganese | 1 | 2010 | 408 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2018 | 4147 | 0.080 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 3076 | 0.080 |
Why?
|
| Retroviridae Infections | 1 | 2008 | 151 | 0.080 |
Why?
|
| Thromboembolism | 2 | 2004 | 983 | 0.080 |
Why?
|
| Stem Cell Transplantation | 1 | 2016 | 1618 | 0.070 |
Why?
|
| Rats | 5 | 2018 | 24265 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2009 | 423 | 0.070 |
Why?
|
| Hair | 1 | 2010 | 483 | 0.070 |
Why?
|
| Atrophy | 3 | 2021 | 1576 | 0.070 |
Why?
|
| Caregivers | 2 | 2019 | 2074 | 0.070 |
Why?
|
| Massachusetts | 2 | 2010 | 8662 | 0.070 |
Why?
|
| Magnesium | 1 | 2010 | 813 | 0.070 |
Why?
|
| Nephrotic Syndrome | 1 | 1991 | 389 | 0.070 |
Why?
|
| Positive-Pressure Respiration | 1 | 2011 | 632 | 0.070 |
Why?
|
| Dyslipidemias | 2 | 2011 | 848 | 0.070 |
Why?
|
| Dogs | 1 | 2012 | 3910 | 0.070 |
Why?
|
| Life Tables | 2 | 2004 | 370 | 0.070 |
Why?
|
| Lithium | 1 | 2010 | 601 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2020 | 12695 | 0.070 |
Why?
|
| Myography | 1 | 2007 | 109 | 0.070 |
Why?
|
| Dyspnea | 1 | 2014 | 1298 | 0.070 |
Why?
|
| Thrombopoietin | 1 | 2008 | 223 | 0.070 |
Why?
|
| Military Personnel | 1 | 2015 | 1132 | 0.070 |
Why?
|
| Monocytes | 2 | 2014 | 2593 | 0.070 |
Why?
|
| Electromyography | 3 | 2020 | 1391 | 0.070 |
Why?
|
| International Cooperation | 3 | 2018 | 1421 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 12220 | 0.070 |
Why?
|
| Body Height | 1 | 2012 | 1574 | 0.070 |
Why?
|
| Australia | 2 | 2021 | 1167 | 0.070 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 2006 | 69 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2010 | 692 | 0.070 |
Why?
|
| Heat-Shock Proteins | 1 | 2009 | 822 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2022 | 5522 | 0.070 |
Why?
|
| Logistic Models | 2 | 2013 | 13403 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 3 | 2011 | 2714 | 0.060 |
Why?
|
| Prospective Studies | 11 | 2019 | 53187 | 0.060 |
Why?
|
| Stroke | 2 | 2019 | 9963 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2014 | 1852 | 0.060 |
Why?
|
| Carbon Radioisotopes | 2 | 2017 | 592 | 0.060 |
Why?
|
| Occupational Exposure | 1 | 2015 | 1794 | 0.060 |
Why?
|
| Free Radical Scavengers | 1 | 2005 | 217 | 0.060 |
Why?
|
| Fatty Acids | 2 | 2023 | 1806 | 0.060 |
Why?
|
| Functional Laterality | 1 | 2012 | 2290 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2015 | 2658 | 0.060 |
Why?
|
| Cytoskeleton | 1 | 1990 | 1185 | 0.060 |
Why?
|
| Cerebellar Neoplasms | 1 | 1989 | 585 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2012 | 2585 | 0.060 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 729 | 0.060 |
Why?
|
| Medulloblastoma | 1 | 1989 | 681 | 0.060 |
Why?
|
| Phenotype | 7 | 2014 | 16331 | 0.060 |
Why?
|
| Drug Tolerance | 1 | 2005 | 375 | 0.060 |
Why?
|
| Neurons, Afferent | 1 | 2006 | 508 | 0.060 |
Why?
|
| Endogenous Retroviruses | 1 | 2005 | 112 | 0.060 |
Why?
|
| Blotting, Western | 2 | 2009 | 5180 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2006 | 1676 | 0.060 |
Why?
|
| User-Computer Interface | 1 | 2010 | 1426 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 2019 | 2838 | 0.060 |
Why?
|
| Data Collection | 2 | 2014 | 3339 | 0.060 |
Why?
|
| Delivery of Health Care | 2 | 2022 | 5304 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2006 | 600 | 0.060 |
Why?
|
| Electric Impedance | 1 | 2007 | 727 | 0.060 |
Why?
|
| Ciliary Neurotrophic Factor | 1 | 2003 | 79 | 0.060 |
Why?
|
| Maximum Tolerated Dose | 1 | 2005 | 891 | 0.060 |
Why?
|
| Vitamin D | 1 | 2017 | 3211 | 0.060 |
Why?
|
| Sickness Impact Profile | 1 | 2004 | 304 | 0.060 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2008 | 740 | 0.060 |
Why?
|
| Gastrointestinal Diseases | 2 | 2018 | 1167 | 0.060 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2006 | 555 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2011 | 2036 | 0.060 |
Why?
|
| Drug Approval | 1 | 2009 | 740 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2003 | 68 | 0.060 |
Why?
|
| False Negative Reactions | 1 | 2004 | 587 | 0.060 |
Why?
|
| Hybrid Cells | 1 | 2003 | 441 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 5133 | 0.050 |
Why?
|
| Linoleic Acids | 1 | 2022 | 38 | 0.050 |
Why?
|
| Military Medicine | 1 | 2005 | 176 | 0.050 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2003 | 149 | 0.050 |
Why?
|
| Risk | 4 | 2016 | 9679 | 0.050 |
Why?
|
| Adjuvants, Immunologic | 1 | 2008 | 1000 | 0.050 |
Why?
|
| Diffusion Tensor Imaging | 3 | 2018 | 2304 | 0.050 |
Why?
|
| Muscle Contraction | 2 | 2007 | 1241 | 0.050 |
Why?
|
| Case-Control Studies | 6 | 2019 | 21719 | 0.050 |
Why?
|
| Genotype | 6 | 2012 | 12946 | 0.050 |
Why?
|
| Cystatin C | 3 | 2010 | 250 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3130 | 0.050 |
Why?
|
| Comorbidity | 3 | 2015 | 10372 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2004 | 759 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3236 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2008 | 1015 | 0.050 |
Why?
|
| Fatty Acids, Omega-6 | 1 | 2023 | 227 | 0.050 |
Why?
|
| Injections, Intraventricular | 1 | 2002 | 230 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 1675 | 0.050 |
Why?
|
| Bone Morphogenetic Protein 7 | 1 | 2002 | 112 | 0.050 |
Why?
|
| Headache | 2 | 2020 | 1219 | 0.050 |
Why?
|
| Neoplastic Stem Cells | 1 | 1989 | 1376 | 0.050 |
Why?
|
| Arm | 1 | 2004 | 589 | 0.050 |
Why?
|
| Cell Death | 1 | 2007 | 1695 | 0.050 |
Why?
|
| Esters | 1 | 2022 | 210 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2015 | 11695 | 0.050 |
Why?
|
| Basal Ganglia Diseases | 2 | 2000 | 149 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 163 | 0.050 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2006 | 602 | 0.050 |
Why?
|
| Genome, Human | 2 | 2012 | 4420 | 0.050 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2009 | 2014 | 0.050 |
Why?
|
| Off-Label Use | 1 | 2022 | 169 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2024 | 371 | 0.050 |
Why?
|
| Organic Chemicals | 1 | 2001 | 211 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 14720 | 0.050 |
Why?
|
| Survival | 2 | 2011 | 162 | 0.050 |
Why?
|
| Drug Design | 1 | 2006 | 1078 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2003 | 391 | 0.050 |
Why?
|
| Motor Activity | 2 | 2020 | 2714 | 0.050 |
Why?
|
| Median Nerve | 1 | 2020 | 132 | 0.050 |
Why?
|
| Reference Standards | 1 | 2004 | 1020 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 35342 | 0.050 |
Why?
|
| Vitamin E | 1 | 2005 | 869 | 0.050 |
Why?
|
| Phosphorylation | 2 | 2021 | 8436 | 0.050 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2010 | 6030 | 0.050 |
Why?
|
| Pain | 1 | 2015 | 4961 | 0.050 |
Why?
|
| Wheelchairs | 1 | 2020 | 77 | 0.050 |
Why?
|
| Fatal Outcome | 2 | 2020 | 1849 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2006 | 942 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2003 | 638 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2001 | 772 | 0.040 |
Why?
|
| Action Potentials | 4 | 2014 | 1814 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2004 | 657 | 0.040 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2023 | 546 | 0.040 |
Why?
|
| Registries | 1 | 2015 | 8077 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 289 | 0.040 |
Why?
|
| Databases as Topic | 1 | 2001 | 475 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1989 | 2940 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 12071 | 0.040 |
Why?
|
| Pharmaceutical Preparations | 1 | 2008 | 1071 | 0.040 |
Why?
|
| Thiazolidines | 1 | 1999 | 74 | 0.040 |
Why?
|
| Neural Conduction | 1 | 2020 | 468 | 0.040 |
Why?
|
| Pyrrolidonecarboxylic Acid | 1 | 1999 | 65 | 0.040 |
Why?
|
| Tetrabenazine | 1 | 2019 | 18 | 0.040 |
Why?
|
| Behavioral Symptoms | 1 | 2021 | 175 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 2001 | 694 | 0.040 |
Why?
|
| Basal Ganglia | 2 | 1999 | 545 | 0.040 |
Why?
|
| Leukocytosis | 1 | 2020 | 247 | 0.040 |
Why?
|
| Ireland | 1 | 2019 | 160 | 0.040 |
Why?
|
| Microglia | 3 | 2014 | 1261 | 0.040 |
Why?
|
| Trinucleotide Repeats | 1 | 2020 | 261 | 0.040 |
Why?
|
| Chorea | 1 | 1999 | 74 | 0.040 |
Why?
|
| Injections | 1 | 2002 | 840 | 0.040 |
Why?
|
| Periodicity | 1 | 2000 | 363 | 0.040 |
Why?
|
| Rats, Transgenic | 1 | 2018 | 71 | 0.040 |
Why?
|
| Safety | 1 | 2003 | 1185 | 0.040 |
Why?
|
| Sex Factors | 4 | 2020 | 10392 | 0.040 |
Why?
|
| Organizations, Nonprofit | 1 | 2019 | 104 | 0.040 |
Why?
|
| Veterans | 1 | 2012 | 2513 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2020 | 23320 | 0.040 |
Why?
|
| Survival of Motor Neuron 2 Protein | 1 | 2017 | 48 | 0.040 |
Why?
|
| Uncertainty | 1 | 2023 | 725 | 0.040 |
Why?
|
| Stroop Test | 1 | 2017 | 62 | 0.040 |
Why?
|
| Ventilators, Mechanical | 1 | 2020 | 292 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2014 | 6452 | 0.040 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2019 | 189 | 0.040 |
Why?
|
| Survival of Motor Neuron 1 Protein | 1 | 2017 | 64 | 0.040 |
Why?
|
| DNA, Mitochondrial | 1 | 2003 | 814 | 0.040 |
Why?
|
| Antibody Formation | 1 | 2022 | 1402 | 0.040 |
Why?
|
| Respiratory Muscles | 1 | 2018 | 140 | 0.040 |
Why?
|
| Probability | 1 | 2023 | 2502 | 0.040 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2019 | 242 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2009 | 4554 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2007 | 2867 | 0.040 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 1999 | 599 | 0.040 |
Why?
|
| Risperidone | 1 | 2000 | 383 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2019 | 353 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2007 | 1237 | 0.040 |
Why?
|
| Marital Status | 1 | 2019 | 437 | 0.040 |
Why?
|
| Cell Line, Transformed | 2 | 2007 | 898 | 0.040 |
Why?
|
| Cross-Sectional Studies | 5 | 2021 | 24913 | 0.040 |
Why?
|
| Spirometry | 1 | 2020 | 862 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2008 | 4328 | 0.040 |
Why?
|
| Occipital Lobe | 1 | 1999 | 380 | 0.040 |
Why?
|
| Pandemics | 3 | 2022 | 8328 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2009 | 107 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 381 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2018 | 563 | 0.040 |
Why?
|
| Positron-Emission Tomography | 3 | 2018 | 6259 | 0.040 |
Why?
|
| Italy | 1 | 2019 | 828 | 0.040 |
Why?
|
| Apathy | 1 | 2017 | 96 | 0.040 |
Why?
|
| Prealbumin | 2 | 2010 | 210 | 0.040 |
Why?
|
| Aspirin | 1 | 2008 | 3278 | 0.040 |
Why?
|
| Glutathione | 1 | 1999 | 586 | 0.040 |
Why?
|
| Forecasting | 1 | 2005 | 2948 | 0.040 |
Why?
|
| Muscle Cramp | 1 | 2016 | 35 | 0.040 |
Why?
|
| Sodium Chloride | 1 | 2018 | 625 | 0.030 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 11363 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 390 | 0.030 |
Why?
|
| Clozapine | 1 | 2000 | 498 | 0.030 |
Why?
|
| Cells, Cultured | 4 | 2014 | 19223 | 0.030 |
Why?
|
| Cystatins | 2 | 2006 | 55 | 0.030 |
Why?
|
| Erythromycin | 1 | 1996 | 120 | 0.030 |
Why?
|
| Nitric Oxide Synthase | 1 | 1999 | 916 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2018 | 1104 | 0.030 |
Why?
|
| Receptors, GABA | 1 | 2017 | 288 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 1991 | 3123 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2569 | 0.030 |
Why?
|
| Child | 4 | 2023 | 77478 | 0.030 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 3239 | 0.030 |
Why?
|
| Cell Survival | 2 | 2005 | 5872 | 0.030 |
Why?
|
| Risk Factors | 6 | 2020 | 72145 | 0.030 |
Why?
|
| Interleukin-2 | 1 | 2022 | 1887 | 0.030 |
Why?
|
| Oligoribonucleotides, Antisense | 1 | 2014 | 15 | 0.030 |
Why?
|
| Dependovirus | 1 | 2020 | 706 | 0.030 |
Why?
|
| World War II | 1 | 2015 | 59 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2303 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 1581 | 0.030 |
Why?
|
| Neurologic Examination | 2 | 2014 | 931 | 0.030 |
Why?
|
| Oximetry | 1 | 2018 | 467 | 0.030 |
Why?
|
| Lumbosacral Region | 1 | 2016 | 310 | 0.030 |
Why?
|
| Sheep | 1 | 1997 | 1437 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2005 | 2896 | 0.030 |
Why?
|
| Apolipoproteins E | 2 | 2014 | 1438 | 0.030 |
Why?
|
| Acetylation | 2 | 2009 | 1085 | 0.030 |
Why?
|
| Kidney Neoplasms | 1 | 1991 | 4229 | 0.030 |
Why?
|
| Language | 1 | 2023 | 1458 | 0.030 |
Why?
|
| Troponin | 1 | 2018 | 524 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 3 | 2014 | 4465 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2014 | 2885 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2006 | 503 | 0.030 |
Why?
|
| Social Perception | 1 | 2017 | 424 | 0.030 |
Why?
|
| Learning | 1 | 2023 | 1705 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2020 | 1538 | 0.030 |
Why?
|
| Lactic Acid | 1 | 1999 | 1132 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 361 | 0.030 |
Why?
|
| Research Personnel | 1 | 2018 | 573 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 1998 | 1792 | 0.030 |
Why?
|
| Cerebral Arteries | 1 | 1995 | 492 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2014 | 270 | 0.030 |
Why?
|
| Half-Life | 1 | 2014 | 658 | 0.030 |
Why?
|
| Prednisone | 1 | 2018 | 1567 | 0.030 |
Why?
|
| Heterozygote | 1 | 2019 | 2790 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 21821 | 0.030 |
Why?
|
| Employment | 1 | 2019 | 1124 | 0.030 |
Why?
|
| Synapses | 1 | 2021 | 1724 | 0.030 |
Why?
|
| Blood Platelets | 1 | 2003 | 2506 | 0.030 |
Why?
|
| Gene Expression | 1 | 2005 | 7790 | 0.030 |
Why?
|
| Dipeptidyl-Peptidases and Tripeptidyl-Peptidases | 1 | 2012 | 88 | 0.030 |
Why?
|
| Algorithms | 4 | 2019 | 13853 | 0.030 |
Why?
|
| Electric Stimulation | 2 | 2007 | 1770 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2019 | 2713 | 0.030 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 963 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2008 | 17400 | 0.020 |
Why?
|
| Antigens, Ly | 1 | 2012 | 291 | 0.020 |
Why?
|
| Europe | 1 | 2018 | 3339 | 0.020 |
Why?
|
| Canada | 1 | 2016 | 2061 | 0.020 |
Why?
|
| Postural Balance | 1 | 2016 | 620 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2017 | 1869 | 0.020 |
Why?
|
| Rats, Inbred Lew | 1 | 2012 | 1161 | 0.020 |
Why?
|
| Genetic Vectors | 1 | 2020 | 3420 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2001 | 3502 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 9581 | 0.020 |
Why?
|
| Alzheimer Disease | 2 | 2003 | 7988 | 0.020 |
Why?
|
| Peptides | 1 | 2022 | 4392 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2012 | 407 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2014 | 2335 | 0.020 |
Why?
|
| Cervical Vertebrae | 1 | 2016 | 973 | 0.020 |
Why?
|
| Dopamine Agonists | 1 | 2012 | 355 | 0.020 |
Why?
|
| Lanthanoid Series Elements | 1 | 2009 | 16 | 0.020 |
Why?
|
| Apyrase | 1 | 2012 | 364 | 0.020 |
Why?
|
| Terminal Care | 1 | 2001 | 1688 | 0.020 |
Why?
|
| Burnout, Professional | 1 | 2018 | 690 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2010 | 4929 | 0.020 |
Why?
|
| Accidental Falls | 1 | 1997 | 1057 | 0.020 |
Why?
|
| Anterior Horn Cells | 1 | 2009 | 19 | 0.020 |
Why?
|
| Indicators and Reagents | 1 | 2010 | 462 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6191 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2012 | 607 | 0.020 |
Why?
|
| Potassium Channels | 1 | 2012 | 562 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2014 | 1538 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 2986 | 0.020 |
Why?
|
| Environmental Exposure | 2 | 2015 | 4231 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 3133 | 0.020 |
Why?
|
| Naphthalenes | 1 | 2009 | 194 | 0.020 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 1989 | 524 | 0.020 |
Why?
|
| Demography | 1 | 2013 | 1650 | 0.020 |
Why?
|
| Carboxylic Ester Hydrolases | 1 | 2008 | 98 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 2749 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 1183 | 0.020 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 782 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4030 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2010 | 6365 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 79 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2019 | 2684 | 0.020 |
Why?
|
| Cell Line | 1 | 2022 | 15994 | 0.020 |
Why?
|
| Smoking | 1 | 2004 | 8969 | 0.020 |
Why?
|
| Incidence | 3 | 2015 | 20928 | 0.020 |
Why?
|
| Glutamine | 1 | 2010 | 574 | 0.020 |
Why?
|
| Thrombolytic Therapy | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2010 | 1683 | 0.020 |
Why?
|
| Age Factors | 2 | 2020 | 18355 | 0.020 |
Why?
|
| History, 20th Century | 1 | 2015 | 2739 | 0.020 |
Why?
|
| Histones | 2 | 2009 | 2597 | 0.020 |
Why?
|
| Hydrolysis | 1 | 2008 | 682 | 0.020 |
Why?
|
| Cell Differentiation | 2 | 2014 | 11470 | 0.020 |
Why?
|
| Palliative Care | 1 | 2001 | 3478 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2022 | 14554 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 8621 | 0.020 |
Why?
|
| Neuroendocrine Secretory Protein 7B2 | 1 | 2005 | 2 | 0.020 |
Why?
|
| Juniperus | 1 | 2005 | 3 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2000 | 3058 | 0.020 |
Why?
|
| Spleen | 1 | 2012 | 2359 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 187 | 0.020 |
Why?
|
| Energy Intake | 1 | 2014 | 2147 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2019 | 3748 | 0.020 |
Why?
|
| Dietary Supplements | 2 | 2011 | 3294 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2018 | 13814 | 0.020 |
Why?
|
| Psychomotor Performance | 2 | 2007 | 1895 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2017 | 2736 | 0.020 |
Why?
|
| Immunoassay | 1 | 2009 | 752 | 0.020 |
Why?
|
| Emotions | 1 | 2017 | 2657 | 0.020 |
Why?
|
| Paresthesia | 1 | 2006 | 162 | 0.020 |
Why?
|
| Tracheostomy | 1 | 2009 | 400 | 0.020 |
Why?
|
| Self Report | 1 | 2016 | 3548 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2012 | 1503 | 0.020 |
Why?
|
| Virus Latency | 1 | 2008 | 356 | 0.020 |
Why?
|
| Sleep | 1 | 2021 | 4604 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2021 | 16665 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 3504 | 0.020 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 3639 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2000 | 3040 | 0.020 |
Why?
|
| Cholesterol | 1 | 2014 | 2895 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 1791 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2010 | 1167 | 0.020 |
Why?
|
| Cytochromes c | 1 | 2005 | 180 | 0.020 |
Why?
|
| Biological Assay | 1 | 2008 | 652 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2012 | 1057 | 0.020 |
Why?
|
| Curcumin | 1 | 2005 | 95 | 0.020 |
Why?
|
| Child, Preschool | 2 | 2017 | 40955 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2007 | 23387 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2014 | 4143 | 0.010 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2004 | 67 | 0.010 |
Why?
|
| Gene Regulatory Networks | 1 | 2012 | 1707 | 0.010 |
Why?
|
| Death Certificates | 1 | 2004 | 169 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 3920 | 0.010 |
Why?
|
| Molecular Weight | 1 | 2006 | 2255 | 0.010 |
Why?
|
| Placebo Effect | 1 | 2007 | 502 | 0.010 |
Why?
|
| Potassium Cyanide | 1 | 2003 | 16 | 0.010 |
Why?
|
| RNA Interference | 1 | 2012 | 2890 | 0.010 |
Why?
|
| Cognition | 1 | 2021 | 6722 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2012 | 1889 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2008 | 1725 | 0.010 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2003 | 99 | 0.010 |
Why?
|
| Metabolomics | 1 | 2011 | 1467 | 0.010 |
Why?
|
| Weight Loss | 1 | 2014 | 2604 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2006 | 474 | 0.010 |
Why?
|
| Mass Spectrometry | 1 | 2010 | 2203 | 0.010 |
Why?
|
| Free Radicals | 1 | 2003 | 236 | 0.010 |
Why?
|
| Inflammation | 1 | 2022 | 10578 | 0.010 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 7770 | 0.010 |
Why?
|
| Cell Fusion | 1 | 2003 | 297 | 0.010 |
Why?
|
| Cell Respiration | 1 | 2003 | 200 | 0.010 |
Why?
|
| Spouses | 1 | 2005 | 284 | 0.010 |
Why?
|
| Electron Transport | 1 | 2003 | 211 | 0.010 |
Why?
|
| Hippocampus | 1 | 2014 | 3661 | 0.010 |
Why?
|
| Protein Binding | 1 | 2014 | 9387 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2008 | 3701 | 0.010 |
Why?
|
| Quality Control | 1 | 2004 | 841 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2012 | 4024 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 2019 | 5024 | 0.010 |
Why?
|
| Early Diagnosis | 1 | 2006 | 1184 | 0.010 |
Why?
|
| Electrophysiology | 1 | 2004 | 1309 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2005 | 647 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 12242 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2005 | 2049 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2008 | 3587 | 0.010 |
Why?
|
| Protein Precursors | 1 | 2005 | 1154 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2012 | 15494 | 0.010 |
Why?
|
| Databases, Genetic | 1 | 2007 | 1780 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2008 | 3001 | 0.010 |
Why?
|
| Face | 1 | 2006 | 993 | 0.010 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2006 | 700 | 0.010 |
Why?
|
| Syndrome | 1 | 2006 | 3248 | 0.010 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2000 | 108 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 8925 | 0.010 |
Why?
|
| Clone Cells | 1 | 2003 | 1692 | 0.010 |
Why?
|
| Injections, Intraperitoneal | 1 | 1999 | 424 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2008 | 4187 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2007 | 4742 | 0.010 |
Why?
|
| Epidemiologic Methods | 1 | 2004 | 1364 | 0.010 |
Why?
|
| Sex Distribution | 1 | 2004 | 2295 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2005 | 2970 | 0.010 |
Why?
|
| International Classification of Diseases | 1 | 2004 | 865 | 0.010 |
Why?
|
| Viral Load | 1 | 2008 | 3292 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2008 | 4211 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 2593 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2005 | 1434 | 0.010 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 2566 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2003 | 1213 | 0.010 |
Why?
|
| Behavior, Animal | 1 | 2005 | 1882 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2003 | 880 | 0.010 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 12958 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2012 | 10472 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2005 | 2500 | 0.010 |
Why?
|
| Sample Size | 1 | 2000 | 844 | 0.010 |
Why?
|
| Infant | 1 | 2017 | 35070 | 0.010 |
Why?
|
| Locomotion | 1 | 1998 | 378 | 0.010 |
Why?
|
| Prevalence | 1 | 2012 | 15194 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2005 | 6171 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 2077 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2001 | 3510 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2008 | 3439 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2003 | 6313 | 0.010 |
Why?
|
| Family | 1 | 2005 | 3144 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2005 | 5867 | 0.010 |
Why?
|
| Life Style | 1 | 2004 | 3824 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2012 | 12164 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1995 | 20086 | 0.010 |
Why?
|
| Alleles | 1 | 2003 | 6931 | 0.010 |
Why?
|
| Educational Status | 1 | 2000 | 2533 | 0.010 |
Why?
|
| Reaction Time | 1 | 1998 | 2092 | 0.010 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 5851 | 0.010 |
Why?
|
| Genomics | 1 | 2006 | 5692 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 9410 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 13029 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 5948 | 0.010 |
Why?
|